- Home
- CYRX vs ERAS Comparison
CYRX vs ERAS Comparison
Compare CYRX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 1.0B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYRX | ERAS |
|---|---|---|
| Price | $8.36 | $15.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $12.94 | $11.38 |
| AVG Volume (30 Days) | 416.8K | ★ 4.2M |
| Earning Date | 03-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 36.23 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $10.92 | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $5.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.63 | $1.01 |
| 52 Week High | $11.45 | $16.14 |
Technical Indicators
Market Signals| Indicator | CYRX | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 64.22 |
| Support Level | $7.95 | $1.50 |
| Resistance Level | $8.52 | $16.14 |
| Average True Range (ATR) | 0.39 | 1.09 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 75.13 | 87.52 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.